A once-daily drug has been launched in the UK for the symptoms of overactive bladder.
Mirabegron (Betmigatm) is the first of a new drug class, known as oral β3-adrenoceptor agonists, which work in a different way to antimuscarinics.
Mirabegron causes relaxation of the bladder muscle during the storage phase of the micturition cycle, improving the storage capacity of the bladder without inhibiting bladder voiding, according to its manufacturer Astellas Pharma.
The drug was launched on 27 february, prompting the National Institute for Health and Clinical Excellence to describe it as a “welcome alternative to current available treatments”.
It announced on 1 March that it had begun a consultation on draft guidance, which provisionally recommended the use of mirabegron for the treatment of overactive bladder syndrome for patients in whom antimuscarinic drugs are not suitable.
NICE chief executiveSir Andrew Dillon said: “Offering mirabegron as an option for treatment, with clear advice about its potential benefits and side effects will help improve quality of life for people living with this distressing condition.”
Consultees, including the manufacturer, healthcare professionals and members of the public are now able to comment on the preliminary NICE recommendations for the use of mirabegron.
The recommendations will be available for public consultation from 1-22 March 2013. Comments received during the consultation will be fully considered by the committee and following this meeting the next draft guidance will be issued, NICE said.